Depression in older adults significantly reduces quality of life and is commonly associated with dysfunctional attitudes and negative perceptions of aging. While pharmacotherapy remains the dominant treatment modality, its limitations in fully addressing underlying cognitive mechanisms have underscored the need for innovative and sustainable psychosocial interventions. The Metacognitive Training–Silver (MCT-Silver) program is designed specifically to enhance cognition and metacognition in the elderly.

This study aimed to evaluate the effectiveness of the MCT-Silver program in improving depressive symptoms, dysfunctional attitudes, metacognitive beliefs, and perceptions of aging in older adults diagnosed with depression.

This randomized controlled experimental study employed a pretest-posttest design with 3-month follow-up. A total of 50 elderly individuals (≥60 years) with a clinical diagnosis of depression were randomized into intervention (n=24) and control (n=26) groups. The intervention group received an 8-week MCT-Silver program, while the control group received routine care. Data were collected at three time points using validated tools: Beck Depression Inventory, Dysfunctional Attitude Scale, Metacognition Questionnaire-30, and the Attitudes to Aging Questionnaire. Statistical analysis included Pearson Chi-Square, independent samples t-test, Mann–Whitney U, and non-parametric repeated measures ANOVA.

Participants’ mean ages were 67.50 ± 5.28 (intervention) and 68.88 ± 5.04 (control), with no baseline differences. Compared to the control group, the intervention group demonstrated statistically significant reductions in depressive symptoms (post p<0.001; 3-month follow-up p<0.001), dysfunctional attitudes (post p=0.002; follow-up p<0.001), and maladaptive metacognitive beliefs (post and follow-up p<0.001). Additionally, significant improvements were observed in attitudes toward aging at both post-intervention and follow-up assessments (p<0.001). No adverse events were reported.

Findings indicate that the MCT-Silver program is a promising and feasible intervention for older adults with depression. It not only reduces depressive symptoms but also modifies dysfunctional cognition and enhances metacognitive capacity, contributing to a more adaptive and positive perception of aging. Incorporating this program into psychiatric nursing practice may contribute to enhanced geriatric mental health outcomes and support holistic, nurse-led interventions in late-life depression management.

None Declared

Serious mental disorders, including depression, schizophrenia, and bipolar disorder, have a prevalence of 5.5%, being more common in women. Physical health problems frequently accompany these disorders, increasing mortality and reducing quality of life due to conditions such as cardiovascular disease, diabetes, and obesity. The growing elderly population with mental disorders highlights the importance of addressing their physical health. Yet, inadequate knowledge among healthcare providers complicates access to comprehensive physical care for these individuals. This study aims to examine the physical health status of elderly patients with serious mental disorders.

This study aims to comprehensively assess the physical health status of elderly individuals diagnosed with serious mental disorders (such as depression, schizophrenia, and bipolar disorder), by identifying co-occurring medical conditions, evaluating risk factors, and highlighting neglected health parameters that may compromise quality of life and increase mortality risk.

Seventy-two elderly patients from a psychiatric outpatient clinic in Istanbul participated. Inclusion criteria were DSM-V diagnosis, age 60 or over. Data were collected via face-to-face interviews and physical examinations using the Individual Characteristics Form, Health Improvement Profile, and Mini Nutritional Assessment. Data analysis utilized SPSS v.29.0, with significance at p<0.05.

Participants’ mean age was 68.51±5.67 years; 55.6% were female, and 81.9% unemployed. Mini Nutritional Assessment scores averaged 11.54±1.71, indicating 58.3% had normal nutritional status. Frequently red-flagged parameters included waist circumference (44.1%), blood pressure, blood glucose, dental, eye, breast/prostate examinations, foot care, exercise, and sleep patterns, whereas smoking, alcohol consumption, and substance use were predominantly normal. Green-flagged parameters were body temperature, smoking and alcohol consumption, fluid intake, urinary elimination, bowel habits, substance use, and caffeine intake.

Findings indicate significant physical health risks among elderly psychiatric patients, highlighting neglect in key health parameters. Regular health screening, multidisciplinary follow-up, professional training, individualized counseling, caregiver involvement, and targeted interventions are essential to improve health outcomes.

None Declared

Alzheimer’s disease (AD) leads to progressive decline in cognitive and functional abilities, with activities of daily living (ADL) serving as a key indicator of disease severity. Gait speed and grip strength are recognized as markers of physical and cognitive health, but their combined and mediating roles in AD remain insufficiently studied.

This study aims to investigate the effects of gait speed and grip strength on ADL and their mediating roles between brain pathology and ADL in patients with AD.

We retrospectively analyzed 150 patients aged ≥65 years diagnosed with AD at Jeju National University Hospital (2017–2024). Data included gait speed, grip strength, ADL, Clinical Dementia Rating Sum of Box (CDR-SB), CERAD neuropsychological assessments, and brain MRI measures (hippocampal volume and white matter hyperintensities (WMH)). Multiple regression and path analyses were conducted to examine the direct, interactive, and mediating effects of gait speed and grip strength on ADL and dementia severity.

Multivariate regression analysis revealed that slower gait speed (β = −0.28, p = 0.024) and weaker grip strength (β = −0.23, p = 0.012) were independently associated with lower ADL performance. A significant interaction effect between gait speed and grip strength was observed, explaining additional variance in ADL decline beyond individual effects (ΔR2 = 0.06, p < 0.01). Increased WMH volume was significantly correlated with slower gait speed (β = −0.30, p < 0.001) and weaker grip strength (β = −0.11, p = 0.042). Path analysis further demonstrated that motor performance partially mediated the relationship between WMH volume and ADL decline (β= 0.18, 95% CI: 0.11–0.26).

This study demonstrates that gait speed and grip strength serve as important independent predictors of functional decline in Alzheimer’s disease, with their combined assessment providing enhanced predictive value for ADL deterioration. Motor performance serves as a critical link between brain pathology and functional outcomes, highlighting the importance of incorporating motor assessments into AD management and progression monitoring.This study aims to investigate the effects of gait speed and grip strength on ADL and their mediating roles between brain pathology and ADL in patients with AD.

None Declared

Methods of neurostimulation have been used to treat neurological and neuropsychiatric disorders. Several methods of non-invasive brain stimulation have been investigated, including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS) and transcranial pulse stimulation (TPS). While ECT, TMS and tDCS have been studied extensively, there is an urgent need for more research on TPS. In the context of Alzheimer’s disease, for example, some studies have demonstrated favorable outcomes when TPS was used as a neurostimulation method. However, this method has yet to be incorporated into clinical practice due to the inability to conclusively assess its effectiveness, which is influenced by several factors.

A new method of neurostimulation, TPS, will be presented. The results of a recent study that used TPS on patients with mild to moderate Alzheimer’s disease (AD) will also be presented. The study aims to investigate whether cognitive performance increases significantly and depressive symptom severity decreases significantly.

Cognitive performance (MoCA) and depressive symptoms (GDS) of patients with mild or moderate early- or late-onset AD, will be assessed at baseline (t1), three months (t2), six months (t3) and nine months (t4) following treatment with TPS. For this monocenter, longitudinal study, participants will be recruited from an outpatient setting at a specialized psychiatric-psychotherapeutic clinic in Lower Saxony, Germany.

Preliminary data; repeated measures ANOVA; mean scores MoCA t1 = 13,9 vs. t2 = 14,1 vs. t3 = 14,5 vs. t4 = 14,4 (F(2, 66) = .749, n.s.), mean scores GDS t1 = 9,5 vs. t2 = 7,6 vs. t3 = 6,8 vs. t4 = 5,9 (F(2, 32 = 4.410, p ˂ .05). n = 40.

The results suggest that cognitive performance can be stabilized and depressive symptoms can be reduced by using TPS in patients with mild-to-moderate Alzheimer’s disease. However, it is important to note that the results are based on a relatively small sample size and lack control conditions, which may limit the generalizability of the findings. Further research is needed to evaluate the effectiveness of TPS treatment for AD and to assess its potential as an add-on therapy that complements previous drug and non-drug approaches.

V. Rößner-Ruff Employee of: No conflict value, C. Penkov Employee of: No conflict value, J. Michaelsen Employee of: No conflict value, J. Krieger Employee of: No conflict value, K. Friedrich Employee of: No conflict value, M. Ziegenbein Employee of: No conflict value

Meditation may serve as a protective factor for mental well-being in older adults, helping them cope with the ongoing challenges of chronic illness.

The objectives are to: 1) explore the emotional experiences of meditation among older adults living with chronic diseases, and 2) examine the impact of meditation on their mental health.

The study involved 426 participants aged 65 to 89 years (M = 74.7; SD = 4.76) from Portuguese, English, and Brazilian backgrounds. Data were collected through in-depth, semi-structured interviews and analyzed using content analysis to identify key themes from participants’ experiences.

For the first objective, six themes emerged: Navigating illness and physical decline (90.4%), Seeking meaning and purpose in life (86.6%), Strengthening self-identity (72.5%), Experiencing reduced dependence and pain (70.2%); Cultivating hopefulness (64.8%); and Prioritizing effective disease management (62.0%). For the second objective, three themes were identified: Reduced emotional burden (83.8%), Decrease in depressive symptoms (78.6%), and Fewer emotional outbursts (52.1%). Portuguese participants emphasized navigating the challenges of illness and physical decline, whereas Brazilian participants placed greater importance on seeking life’s purpose. In contrast, English participants highlighted a stronger connection between meditation and strengthening their self-identity.

The study reveals meditation’s significant impact on enhancing both physical and mental health among older adults living with chronic illnesses, demonstrating its value as a multifaceted support strategy in later years.

Chronic conditions; meditation; mental health; older adults; qualitative study.

None Declared

Depression, anxiety, and insomnia represent the most prevalent psychiatric comorbidities in cancer populations, significantly impacting quality of life, treatment adherence, and survival outcomes. These conditions are increasingly recognized as complex neurobiological phenomena rather than simple psychological reactions to cancer diagnosis.

To synthesize current evidence on the epidemiology, pathophysiology, assessment approaches, and treatment interventions for depression, anxiety, and insomnia in oncologic populations, providing evidence-based insights for clinical practice and research.

Comprehensive review of recent meta-analyses, systematic reviews, and clinical guidelines published between 2023-2025. Key databases included PubMed, EMBASE, and major oncology journals. Priority was given to large-scale meta-analyses and evidence-based clinical practice guidelines from major oncology organizations.

Global meta-analysis of 135,015 cancer survivors from 31 countries revealed prevalence rates of 23.7% for depression, 24.4% for anxiety, and 34.1% for sleep disorders. Pathophysiological mechanisms involve immune-inflammatory processes, hypothalamic-pituitary-adrenal axis dysregulation, and neurotransmitter alterations. Validated screening tools include Hospital Anxiety and Depression Scale, Patient Health Questionnaire-9, Generalized Anxiety Disorder-7, and Insomnia Severity Index. Evidence-based treatments demonstrate strong efficacy: Cognitive Behavioral Therapy shows moderate to large treatment benefits for depression and anxiety, while Cognitive Behavioral Therapy for Insomnia shows very large improvements in sleep quality and duration. Mindfulness-based interventions receive strong American Society of Clinical Oncology recommendations. Pharmacological approaches favor selective serotonin reuptake inhibitors as first-line agents.

Psychiatric comorbidities in cancer require systematic screening and evidence-based treatment. The high prevalence rates underscore the need for integrated psycho-oncology care. Future directions include personalized medicine approaches and prevention-focused interventions targeting inflammatory pathways.

None Declared

Cancer-related cognitive impairment (CRCI) affects up to 75% of cancer patients, significantly impacting quality of life and functional capacity. While traditionally attributed to chemotherapy neurotoxicity, emerging evidence implicates cytokine-mediated neuroinflammation as a central pathophysiological mechanism. The bidirectional communication between peripheral inflammatory processes and central nervous system dysfunction represents a paradigm shift in understanding CRCI etiology.

To synthesize current evidence on cytokine-mediated neuroinflammation in CRCI pathogenesis and evaluate therapeutic implications for psycho-oncology practice, focusing on mechanistic pathways and evidence-based interventions targeting inflammatory processes.

Comprehensive literature review of peer-reviewed publications (2015-2025) examining cytokine involvement in CRCI. Search strategies included PubMed, PMC, and academic databases using terms: “cytokine neuroinflammation,” “cancer cognitive impairment,” “psycho-oncology interventions.” Primary focus on mechanistic studies, clinical trials, and therapeutic intervention research.

Key findings demonstrate that pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) disrupt blood-brain barrier integrity, activate microglia and astrocytes, and alter neurotransmitter systems. Studies showed IL-1β associated with poorer cognitive performance (p=0.023), while IL-6 correlated with perceived cognitive disturbances (p=0.001). Conversely, IL-4 demonstrated neuroprotective effects. Animal models confirm systemic inflammation induces widespread neuroinflammation in hippocampus, cerebellum, and cortical regions. Therapeutic interventions show promise: mindfulness-based stress reduction effectively improves subjective cognitive function, while psychological interventions directly reduce inflammatory markers through HPA axis modulation.

Cytokine-mediated neuroinflammation represents a critical mechanism in CRCI pathogenesis, offering novel therapeutic targets. Psycho-oncological interventions demonstrate dual benefits by addressing psychological distress and modulating underlying inflammatory processes. Integration of mechanistic understanding with evidence-based psychological interventions provides a foundation for personalized, biologically-informed psycho-oncology practice targeting neuroinflammation to improve cognitive outcomes in cancer survivors.

None Declared

People experiencing homelessness (PEH) present high psychiatric comorbidity and reduced survival. Evidence on cancer among PEH and its intersection with addictions and mental health remains scarce in Spain.

1. (1) To estimate cancer burden in PEH.

2. (2) To describe psychiatric comorbidity (substance use disorders [SUD] and other disorders) and its relationship with mortality.

3. (3) To explore differences by sex and origin (Spanish-born vs. foreign-born).

Secondary analysis of a retrospective cohort (Girona, 2006–2020) of PEH through linkage of clinical records (mental health, addictions, primary care, and specialized services). Diagnoses were coded according to ICD-10/11. Prevalence, causes of death, and previously published regression findings (predictors of age at death) are reported.

Cancer was diagnosed in 4.0% of the cohort (n=118) and accounted for 7.9% of deaths with a known cause. Overall mortality was 13.2%, with a mean age at death of 52.4 years. Psychiatric comorbidity was high: SUD in 31.6% and dual pathology in 11.5%. Multivariable models showed lower age at death associated with SUD (alcohol, opioids, cocaine), COPD, CVD, bipolar disorder, and being Spanish-born; cancer was also linked to earlier death. Women displayed worse health and higher mortality than men; Spanish-born participants died almost nine years earlier than foreign-born.

Among PEH, oncological burden coexists with high psychiatric and addictive comorbidity, driving premature mortality. Clinical practice should integrate opportunistic cancer screening and continuity of care with tobacco and SUD treatment programs, coordinate mental health–oncology–primary care pathways, and tailor interventions by sex and origin (immigrant health advantage). Findings support the need for smoke-free residential services and rapid onco-psychiatric referral pathways for PEH.

None Declared

There is a scarcity of research analyzing the risk of cancer in people with schizophrenia based on the type of antipsychotic medication used, especially for those antipsychotics, which are prescribed to the small subset of patients with treatment-resistant schizophrenia.

The aim of this study was to analyze the risk of cancer in people with schizophrenia who used clozapine in Lithuania between 2013 and 2021.

A retrospective cohort study design was used to evaluate the association between clozapine exposure and cancer risk. In this study, we used individual patient records from the Lithuanian Cancer registry and the National Health Insurance Fund (NHIF). In the NHIF database, we identified patients who were reported with schizophrenia (International Classification of Diseases (ICD)-10 code F20) from 2013 to 2021, the type of antipsychotic medications, and dates of prescription. Standardized incidence ratios (SIR) for cancers were calculated as the ratio of the number of observed cancer cases in the clozapine user cohort to the expected number of cancers in the general Lithuanian population.

The final cohort comprised 3473 patients with schizophrenia treated with clozapine and 91 cancer cases were observed. Overall cancer risk in schizophrenia patients who used clozapine was lower in males, but not in females, SIR 0.69 (95% CI 0.52 – 0.92). In our study we observed statistically significant results in prostate cancer, particularly in time-dependent manner, when clozapine was used for more than three years SIR 0.47 (95% CI 0.22 – 0.98). Additionally, for corpus uteri cancer, the risk was significantly increased when clozapine use exceeded three years SIR 2.42 (95% CI 1.21 – 4.83).

Current evidence on the incidence of solid cancers among schizophrenia patients who use clozapine remains very limited. The results of our study highlight the importance of further prospective studies with adequate follow-up to clarify the potential cancer risks and guide clinical decision making.

None Declared

Suicide remains a major global public health concern, and cancer is associated with a significantly increased risk of suicide compared with the general population. The psychological, existential, and social consequences of a cancer diagnosis—including anxiety, depression, reduced quality of life, and feelings of burden—make suicidal ideation a critical yet often under-recognized issue. While patients with cancer frequently discuss death and dying, direct conversations about suicidal thoughts are uncommon.

To explore how the shift from suicide prediction to therapeutic assessment and risk management can be applied in the context of cancer care by using scientific literature from oncology as an application of the model in a theroetical paper.

Drawing on Hawton et al.’s model of therapeutic assessment and risk management instead of prediction (2022)- a framework comprising predisposing, future, modifiable, and protective factors is presented and contextualized for cancer care by integrating evidence from oncology research. Scientific literature with studies from the oncology care was sought for each factor. Articles in English, covering different aspects of being a cancer patient, and not older than 10 years, were included.

Suicidal ideation represents a significant but often underacknowledged dimension of cancer care, affecting both patients and the healthcare professionals who provide support throughout the illness trajectory. It was shown that Hawton’s model is a useful tool för understanding the situation with life threatening diagnosis and suicidal thoughts. Incorporating systematic inquiry into suicidal ideation within routine cancer care encounters may normalize discussions of suicide, reduce stigma, and facilitate earlier identification of distress. The potential outcomes include a reduction in patient and professional suffering and a strengthened capacity of the healthcare system to prevent suicide.

This framework provides clinicians with a way to explore not only the risks that may increase vulnerability but also the strengths and resources that can support resilience. Structured conversations about suicide extend beyond risk management. They affirm life by fostering hope, reducing stigma, and ensuring that patients with cancer feel acknowledged, supported, and understood throughout their illness journey.

Reference: Hawton, K., Lascelles, K., Pitman, A., Gilbert, S., & Silverman, M. (2022). Assessment of suicide risk in mental health practice: shifting from prediction to therapeutic assessment, formulation, and risk management. Lancet Psychiatry, 9(11), 922–928. https://doi.org/10.1016/s2215-0366(22)00232-2

None Declared

Family caregivers provide critical support to individuals undergoing cancer treatment, often at substantial personal cost. Globally, up to 60% experience psychological distress, yet their needs are rarely addressed. In Kenya, data on caregiver mental health are limited despite the rising cancer burden. This study assessed the prevalence of depression and its association with caregiver burden among caregivers at a national oncology center.

To determine depression prevalence and its association with caregiver burden among family caregivers of cancer patients.

A descriptive cross-sectional study recruited 259 caregivers at Kenyatta National Hospital Cancer Treatment Centre via systematic random sampling over two months. Data were collected using an interviewer-administered questionnaire. Depression was measured using the Patient Health Questionnaire-9 (PHQ-9) and caregiver burden with the Zarit Burden Interview (ZBI). Descriptive statistics and logistic regression were performed using SPSS v26.

Depression prevalence was 44.0%, mean PHQ-9 score 9.61 (SD ± 6.6). High caregiver burden was reported by 37.8%, mean ZBI score 16.96 (SD ± 12.15). Caregiver burden was the strongest predictor of depression (p<0.001); those with no/mild burden were over three times more likely to report no depression (OR=3.317). Depression showed no significant association with age, gender, education, or income.

Depression is common among cancer caregivers in Kenya, driven primarily by caregiver burden rather than socio-demographic factors. Findings highlight the need for routine mental health screening, caregiver-focused psychosocial support, and policy measures to address caregiver strain in oncology care.

None Declared

The Acceptance of Illness Scale (AIS) is a widely used questionnaire developed to assess illness acceptance in various conditions, including cancer. The AIS measures the extent to which individuals are able to accept their illness and adapt to the limitations and challenges it imposes on their daily lives. Its latent factor structure has been explored in a few countries; however, the psychometric properties of the scale have not yet been investigated in Hungary.

We aimed to explore the factor structure of the AIS and examine the key psychometric properties of the Hungarian version.

A paper-based survey was administered to patients at the clinics of Semmelweis University, Hungary. The AIS is an 8-item self-report measure with a single subscale. Exploratory and confirmatory factor analyses were conducted to examine its factor structure, and Cronbach’s alpha coefficient was calculated to assess internal consistency. The helplessness/hopelessness and fighting spirit subscales of the Mini-Mental Adjustment to Cancer scale (Mini-MAC) were used to evaluate convergent and divergent validity. Intraclass correlation coefficients will be applied to assess test–retest reliability.

This is ongoing research. To date, 259 participants have completed the questionnaire, and data collection is still in progress. Parallel analysis supported a single-factor solution, indicating a unidimensional structure on which all eight items loaded. The root mean square error of approximation (RMSEA) was acceptable (0.068), and the incremental fit indices [comparative fit index (CFI) = 0.996, Tucker–Lewis index (TLI) = 0.993] exceeded the commonly accepted threshold of 0.90. Cronbach’s alpha was 0.885, which indicated good internal consistency. Convergent and divergent validity with the Mini-MAC subscales showed significant correlations: fighting spirit (r = 0.204, p = 0.001) and helplessness/hopelessness (r = –0.510, p < 0.0001). Test–retest reliability analyses are currently underway.

Preliminary findings support a unidimensional structure of the AIS with good internal consistency. Further validity and reliability analyses will be completed in the coming months, prior to poster presentation. We expect that the Hungarian version of the AIS will demonstrate suitable psychometric properties for use among individuals with physical health conditions, particularly cancer, in Hungary.

None Declared

Sleep disturbances are frequently reported among patients diagnosed with breast cancer. Their severity has been associated with depressive symptoms, anxiety, and fatigue. However, to date, no studies have systematically explored the relationship between insomnia and more specific psychological constructs such as demoralization and perceived dignity.

This study aimed to explore the psychopathological correlates of sleep disturbances in a sample of patients attending the psycho-oncology outpatient clinic of the Breast Unit at a university hospital.

Sixty patients with a diagnosis of breast cancer were recruited. Following an initial psychiatric evaluation, the following psychometric instruments were administered: the Insomnia Severity Index (ISI) to assess insomnia severity and impact; the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms; the Patient Dignity Inventory (PDI) to evaluate different sources of dignity-related distress; and the Demoralization Scale (DS) to assess the presence of demoralization.

The mean PHQ-9 score was 8.31 (SD = 5.30); 27 patients (45%) scored above 9, indicating clinically relevant depressive symptoms. The average PDI score was 39.03 (SD = 14.39). Twenty-one patients (35%) scored above 15 on the ISI, indicative of moderate to severe clinical insomnia. ISI total scores showed significant positive correlations with PHQ-9 scores (r = .478, p < .001), PDI scores (r = .530, p < .001), and all PDI subscales, particularly physical symptom distress (r = .502, p < .001), existential distress (r = .493, p < .001), dependency (r = .573, p < .001), lack of peace of mind (r = .292, p = .024), and lack of perceived social support (r = .343, p = .007). Regarding the Demoralization Scale, ISI scores were significantly correlated with the subscales “loss of meaning” (r = .278, p = .031), “disheartenment” (r = .261, p = .044), and more strongly with “sense of failure” (r = .426, p = .001). The remaining DS subscales (“helplessness” and “dysphoria”) and the DS total scores did not show significant associations with insomnia severity.

In this sample, sleep disturbances emerged as a common clinical issue often associated with depressive symptoms, specific dimensions of demoralization, and dignity-related distress. In our sample, greater insomnia severity was significantly associated with more intense depressive symptoms, increased distress related to dignity in a context of physical symptoms, perceived dependency and lack of social support, and stronger feelings of failure and loss of meaning. These findings support the need for an integrated assessment of sleep and psychological suffering in the care of oncology patients, with the goal of improving overall well-being and quality of life through targeted interventions.

None Declared

In 2020, colorectal cancer (CRC) accounted for over 1.9 million newly diagnosed cases, positioning it as the third most prevalent cancer globally. During the same period, CRC was responsible for approximately 0.9 million fatalities, rendering it the second leading cause of cancer-related mortality worldwide. Significant geographical disparities have been documented concerning the incidence, mortality rates, temporal trends, and projected future burden of colorectal cancer across diverse countries and regions. Concurrently, shifts in the age-specific incidence patterns of CRC have been observed, characterized by a rising incidence among younger individuals, particularly evident in developed nations. Effective colorectal cancer prevention strategies involve two primary approaches: the identification and mitigation of modifiable risk factors, particularly those related to lifestyle (e.g., alcohol consumption, smoking, obesity, and an unhealthy diet), and the enhancement of protective factors (e.g., regular physical activity, adherence to specific chemo preventive medications such as aspirin, and the adoption of a healthy dietary pattern). Colorectal cancer (CRC) screening, a form of secondary prevention, is recognized as an effective prophylactic measure within CRC control programs.

This study aims to evaluate the prevalence of psychiatric morbidities after colorectal surgical procedures, identify associated risk factors for their development, and determine whether improved access to psychological therapies would benefit this patient population.

In our study, 402 patients were investigated prospectively for psychiatric diseases as a complication one year postoperatively.

In our recent cohort of 402 CRC patients, 77 (19.2%) developed at least one new psychiatric diagnosis during follow-up. The most common conditions were mood disorders (4.23%)—predominantly depressive disorders (4%)—and anxiety disorders (3%), followed by delirium and other cognitive disturbances (1.74%).

In conclusion, mental health disorders constitute a pivotal yet insufficiently acknowledged aspect of postoperative care for patients with colorectal cancer (CRC), particularly among those experiencing complications. The integration of systematic psychiatric evaluation and prompt intervention into CRC treatment protocols is crucial for enhancing both oncological outcomes and comprehensive recovery. Mental health is recognized as a fundamental component of oncological patient care, with existing evidence indicating its impact on overall survival.

None Declared

Gastrointestinal (GI) cancers, including stomach, liver, esophageal, pancreatic, and colorectal cancers, represent more than 26% of all malignancies. Colorectal cancer (CRC) represents the third most frequently diagnosed malignancy among both men and women and stands as the second leading cause of cancer-related mortality globally. In 2020, the International Agency for Research on Cancer (IARC) estimated that there were approximately 2 million new cases of CRC and 1 million CRC-related deaths globally. These figures accounted for 10% of the worldwide cancer incidence and 9.4% of all cancer-attributable mortality. Many cancer survivors, including those with colorectal cancer (CRC), commonly experience physical and mental health problems that are typically sequelae of the malignancy and its associated treatments. A cancer diagnosis is frequently intertwined with the presence of mental illness and comorbid health conditions and patients with pre-existing mental illness, in particular, may face a worse overall prognosis, potentially leading to increased mortality. The incidence of new-onset mental health conditions in GI patients is particularly elevated among those with additional medical comorbidities, post-cancer complications, or sequelae directly attributable to the surgical intervention

Ιn this prospective single-center study, we involved 603 patients undergoing stomach, liver, esophageal, pancreatic, or colorectal cancer operations at the Department of General Surgery of the General University Hospital of Patras between January 2019 and December 2023. This research focused on mental diseases as long-term complication that appeared in these patients one year postoperatively.

Psychological and psychiatric support was offered as part of routine practice within the standard patient follow-up and multidisciplinary oncological treatment framework. Consultant psychiatrists performed psychiatric workups and assessments in outpatient clinics. Patients were followed for one year following their GI treatment within the scope of this study.

Of the 603 patients, 126 (20.9%) developed at least one psychiatric diagnosis during the follow-up period. The most frequently observed conditions were mood disorders (20.6%), primarily depressive disorders (19%), and anxiety disorders (12.7%), followed by delirium and other cognitive disturbances (19.5%).

In conclusion, mental health disorders constitute a pivotal yet insufficiently acknowledged aspect of postoperative care for patients with GI cancer, especially among those experiencing complications. Recognizing mental health as a fundamental element of oncological patient care, supported by existing evidence of its influence on overall survival, is paramount.

None Declared

Child dental fear is a common, modifiable barrier to care that predicts avoidance, emergency-driven attendance and poorer oral/psychosocial outcomes in later life. Fear arises through learned and neurobiological (amygdala–HPA) pathways. producing heightened autonomic arousal in the dental setting. Embedding early identification and brief interventions in routine dentistry could change trajectories.

1. (1) Synthesize evidence on the development and maintenance of dental fear in children;

2. (2) appraise subjective (psychometric/observational) vs objective (physiological) assessment for clinical usability;

3. (3) evaluate behavioural/psychological interventions with real-world feasibility;

4. (4) propose a pragmatic, stepped-care pathway linking paediatric dentistry with child mental health.

Critical narrative review across paediatric dentistry, clinical psychology and neurobiology. Inclusion prioritised child-focused studies, validated measures (CFSS-DS, DFSS-SF, DAS, Venham), and interventions (Tell-Show-Do, graded exposure, distraction/VR, CBT-informed approaches; pharmacological adjuncts for severe cases). Each source was logged for credibility, strengths/limits, applicability and convergence/divergence; findings were thematically synthesised (aetiology, measurement, management).

Aetiology: Fear typically begins in childhood via conditioning, modelling (parental anxiety) and information pathways; neurobiology (amygdala/HPA) explains autonomic hyperarousal and avoidance.

Measurement: Subjective tools (CFSS-DS/DFSS-SF) are reliable and chairside-feasible; DAS is less age-specific; observation (Venham) supports non-verbal cases. Objective indices (HR, skin conductance, salivary cortisol) track arousal but are resource-heavy—best for research/specialist clinics. Combining brief subjective screening with selective physiological monitoring optimises validity and practicality.

Interventions: Behavioural methods (Tell-Show-Do, graded exposure, distraction/modelling) consistently reduce fear; dentist-communication micro-skills (predictability, choice, control) are key “active ingredients.” CBT-informed packages and VR are promising; pharmacological support is reserved for severe treatment-blocking anxiety.

Pathway: (i) Screen (DFSS-SF/CFSS-DS); (ii) Match to stepped care (universal communication+behavioural strategies → CBT-informed/VR → specialist/adjunctive pharmacology); (iii) Review to prevent avoidance cycles.

Child dental fear is identifiable and treatable. Embedding screening and stepped behavioural care in routine dentistry, with clear escalation routes, provides a practical bridge to child mental health. Next steps: implement in primary care, test cost-effectiveness of CBT-informed/VR options, and develop low-cost biosensors. This model can reduce avoidance and improve long-term oral-health trajectories.

None Declared

Imposter Syndrome (IS) is characterized by persistent self-doubt and feelings of intellectual fraudulence despite evidence of competence. It is highly prevalent among high-achieving individuals, particularly university students. Although IS is believed to be linked with psychological distress such as anxiety and depression, regional data from the Middle East remain limited. Understanding this phenomenon is vital in environments driven by performance.

This study aimed to assess the prevalence of IS among undergraduate students at Sultan Qaboos University (SQU) and assess its association with depression and anxiety.

A cross-sectional study was conducted among 504 stratified-randomly selected full-time undergraduate students at SQU. Participants completed a validated online questionnaire including the Clance Imposter Phenomenon Scale (CIPS), Patient Health Questionnaire-9 (PHQ-9), and Generalized Anxiety Disorder-7 (GAD-7). Statistical analyses included Pearson’s correlation, chi-square testing, and logistic regression.

IS was present in 56% of participants. CIPS scores were moderately correlated with depression (r = 0.486, p < 0.001) and anxiety (r = 0.472, p < 0.001). Students who experienced imposter syndrome showed a higher probability of developing depressive symptoms (χ2 = 45.63, p < 0.001, OR = 3.49) and anxiety symptoms (χ2 = 32.96, p < 0.001, OR = 2.86). Logistic regression showed that depressive (B = 0.096, p < 0.001) and anxiety symptoms (B = 0.075, p = 0.003) were significant predictors of IS.

This study reveals a strong link between imposterism, depression, and anxiety among students, underscoring the need for targeted counseling interventions and clinical recognition of the phenomenon

None Declared

Undifferentiated connective tissue dysplasia (uCTD) in young women is frequently accompanied by autonomic dysregulation, heightened interoceptive sensitivity, and allostatic load—factors implicated in anxiety. The mechanisms linking uCTD severity with anxiety, particularly circadian autonomic signatures, remain under-characterised.

To test the association between uCTD severity and anxiety, and to examine whether circadian autonomic dysregulation (including the “autonomic paradox”) mediates this link.

Cross-sectional study of 47 women (21–28 years) with verified uCTD. Two severity groups by dysplasia score: subclinical (n=24; DCT<23) vs manifest (n=23; DCT≥24). Anxiety was assessed with the Taylor Manifest Anxiety Scale (TMAS; 0–50). Autonomic proxies comprised 24-h heart-rate-variability (HRV) analysis with Kerdo Index (VIK) and spectral metrics (LF, HF, VLF, LF/HF) plus Index of Centralization (IC); day–night segmentation. Group comparisons and day/night correlations were analysed.

Anxiety was higher with greater uCTD severity (TMAS medians: 14 vs 25; difference=9). A tonic VIK shift occurred from marked vagotonia to formal sympathicotonia (−14.5±4.8 → +2.1±7.4; Δ=16.6; 95%CI 3.99–29.11; p<0.01). Despite sympathicotonia, LF/HF decreased by 23% (0.55±0.20 → 0.42±0.19) with LF −27% (1504→1093 ms2) and HF +17% (3329→3889 ms2)—constituting an “autonomic paradox.” VIK–HRV coupling strengthened at night (LF/HF r: 0.40→0.50; IC r: 0.45→0.55; VLF/HF r: 0.38→0.48). IC indicated pathological nocturnal centralization (physiologically expected to decline at night).

Greater uCTD severity is associated with higher anxiety in young women and with circadian autonomic dysregulation characterised by an “autonomic paradox” and nocturnally reinforced VIK–HRV coupling. These objective metrics (TMAS, VIK/HRV, IC) may support psychiatric risk stratification, staging, and treatment monitoring. Clinically, subclinical uCTD may benefit from vagal-tone maintenance, whereas manifest uCTD warrants restoration of autonomic reciprocity and reduction of allostatic load (sleep regularity, graded activity, breathing-based arousal control, CBT/schema-therapy; pharmacotherapy as indicated).

None Declared

Postpartum anxiety is a mental health concern with adverse effects on maternal well-being, infant development, and family functioning (Ayers et al. Br J Psychiatry 2023; 1:1–8). Symptom overlap with mood disorders and limited screening contribute to underrecognition (Barry et al. JAMA 2023; 329:2163–70). About 20% of women experience clinically significant anxiety during pregnancy and postpartum (Fawcett et al. J Clin Psychiatry 2019; 80:19m12789). No studies have examined postpartum anxiety in Latvia.

To assess the prevalence, severity, and associated sociodemographic and clinical factors of postpartum anxiety among women at their first outpatient gynaecology visit, 4–6 weeks after childbirth.

This cross-sectional study included all consecutive women aged ≥18 years attending Riga Maternity Hospital, Latvia’s largest outpatient clinic, for a routine gynaecologist visit 4–6 weeks postpartum. Anxiety was measured with the Generalized Anxiety Disorder-7 scale (GAD-7) with a cut-off score of 8 chosen, based on sensitivity/specificity analysis. Sociodemographic (age, BMI, ethnicity, education, residence, employment, family income) and clinical/reproductive factors (children <18 years, breastfeeding, abortion history, delivery mode, assisted reproduction, perinatal complications, intrapartum interventions, chronic and gynaecological illness, psychiatric history, abuse during pregnancy, sleep quality, infant temperament) were collected via medical records and questionnaire. Associations were tested with chi-square.

A total of 272 women (mean age 30.66 ± 5.59 years) were assessed. Of these, 82% (n=223) had GAD-7 <8, while 18% (n=49) scored ≥8. Higher anxiety severity (GAD-7 ≥8) was significantly associated with maternal complications during/after delivery (p=0.009), older maternal age (p=0.013), gynaecological illness (p=0.019), history of mood disorder (p=0.026), and emotional abuse (p=0.044). Borderline associations were observed for stressful life events before/during pregnancy (p=0.076) and breastfeeding (p=0.097). No significant associations were found with BMI, residence, ethnicity, smoking, alcohol use, physical abuse, reproductive history, or other clinical factors (all p>0.05).

Postpartum anxiety was common, affecting nearly one in five women. Key risk factors included older maternal age, gynaecological illness, maternal complications, prior mood disorder, and emotional abuse, with possible contributions from stressful life events and breastfeeding. These findings highlight the need for routine postpartum anxiety screening in Latvia.

None Declared

Laryngopharyngeal reflux (LPR) is a common disorder characterized by upper aerodigestive symptoms, with growing evidence suggesting that psychological distress may act as a trigger or exacerbating factor. However, findings remain inconsistent and mostly focused on GERD rather than LPR.

To investigate the correlation between laryngopharyngeal reflux (LPR) and psychological distress in adult Italian patients

LPR was assessed using the Reflux Symptom Index (RSI), Reflux Finding Score (RFS), and 24-hour impedance-pH monitoring. Psychological distress was evaluated with the following clinical tools: the Hospital Anxiety and Depression Scale (HADS), the Hamilton Anxiety Rating Scale (HAM-A), the Hamilton Depression Rating Scale (HAM-D), the Impact of Event Scale-Revised (IES-R), the Insomnia Severity Index (ISI), and the Perceived Stress Scale-10 (PSS-10). Associations between RSI, RFS, and psychological scores were analyzed

A total of 45 LPR patients (Study Group, SG) and 29 healthy controls (CG) were included. Psychological assessments showed significantly higher distress in the SG compared to CG, with the only exception of the ISI. Anxiety levels were greater in LPR patients (HAM-A: 9.53 ± 5.8 vs. 6.79 ± 6.5; p = 0.025), as were anxious-depressive symptoms (HADS, p = 0.029). Depressive symptoms remained on average below the clinical threshold in both groups, though SG scores were close to the cut-off (6.89 ± 4.1 vs. 4.86 ± 5.1; p = 0.010). Perceived stress was significantly higher in the SG, reaching mild-to-moderate levels (21.62 ± 8.1 vs. 13.90 ± 5.5; p < 0.001). Moreover, RSI scores correlated positively with HAM-D, HADS, and HAM-A values.

Patients with LPR showed significantly higher levels of psychological distress, particularly anxiety and perceived stress, compared with healthy controls. These findings suggest that psychological factors may play an important role in the management of LPR and should be taken into account in diagnostic and therapeutic pathways.

None Declared